NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals announced that its board has initiated a stock repurchase program on Wednesday, March 28th 2018, which allows the company to repurchase $7,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 2.7% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.03. The firm had revenue of $14.23 million for the quarter. Avadel Pharmaceuticals had a negative return on equity of 608.01% and a negative net margin of 136.46%. View Avadel Pharmaceuticals' Earnings History.

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Avadel Pharmaceuticals.

3 brokers have issued 1-year price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $6.00 to $15.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $9.00 in the next year. This suggests that the stock has a possible downside of 11.9%. View Analyst Price Targets for Avadel Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.

Media stories about AVDL stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), ZEALAND PHARMA/S (ZEAL), Nabriva Therapeutics (NBRV), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Intra-Cellular Therapies (ITCI), Zogenix (ZGNX), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT), Odonate Therapeutics (ODT) and Enanta Pharmaceuticals (ENTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (9.75%), Broadfin Capital LLC (2.75%), Renaissance Technologies LLC (2.28%), Iridian Asset Management LLC CT (0.83%), Keel Point LLC (0.11%) and Perceptive Advisors LLC (0.02%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP and Broadfin Capital LLC. View Insider Buying and Selling for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Keel Point LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Carmichael Hill & Associates Inc., Steward Partners Investment Advisory LLC and UBS Group AG. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis and Michael S Anderson. View Insider Buying and Selling for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $10.22.

Avadel Pharmaceuticals has a market capitalization of $382.74 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.

The official website for Avadel Pharmaceuticals is http://www.avadel.com/.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]